Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study

Table 1 Lifetime attributable risk for DI-3DCRT and DI-VMAT relative to a free-breathing 3DCRT for INRT treatments with 30 Gy prescribed dose

Cancer site	Mediastinal-both	Mediastinal-both & Supra-both	Mediastinal-both & Supra-left	Mediastinal-left
Breast
3DCRT	0.86	0.84	0.85	0.91
VMAT	2.05	1.82	1.89	1.93
Lung
3DCRT	0.76	0.80	0.78	0.74
VMAT	1.29	1.11	1.17	1.55
Esophagus
3DCRT	0.94	0.98	1.06	0.90
VMAT	1.01	1.12	1.15	1.00
Stomach
3DCRT	0.92	0.91	0.92	0.93
VMAT	0.93	0.93	0.93	0.92
Thyroid
3DCRT	0.89	0.61	0.62	0.93
VMAT	0.88	0.67	0.79	0.93
Bone sarcoma
3DCRT	0.88	0.87	0.82	0.88
VMAT	0.62	0.58	0.60	0.63
Soft tissue sarcoma
3DCRT	0.89	0.83	0.83	0.90
VMAT	0.75	0.65	0.69	0.78
All cancers
3DCRT	0.82	0.82	0.82	0.86
VMAT	1.59	1.36	1.43	1.63

ISSN: 1748-717X